FDA Adverse Event Other Summary report: N

OSTEOSELECT DBM PUTTY

MDR report key: 3012025 · Received March 15, 2013

Report

Report Number
3005168462-2013-00006
Event Type
Other
Date Received
March 15, 2013
Date of Event
January 28, 2013
Report Date
February 21, 2013
Manufacturer
BACTERIN INTERNATIONAL, INC.
Product Code
MQV
PMA / PMN Number
K091321
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MT, US
Reporter Occupation
NOT APPLICABLE

Narratives

Additional Manufacturer Narrative · 1

THE EVENT WAS IDENTIFIED AND REPORTED BY FDA INSPECTORS DURING A ROUTINE INSPECTION OF BACTERIN IN 2012.

Description of Event or Problem · 1

ENDOTOXIN TESTING ON BACTERIN'S OSTEOSELECT DBM PUTTY IS PERFORMED BY AN INDEPENDENT THIRD PARTY FACILITY IN ACCORDANCE WITH A VALIDATED ASSAY. BACTERIN HAD DISCUSSED A RE-TESTING OPTION WITH THE TESTING FACILITY THAT BACTERIN CONSIDERED TO BE CONSISTENT WITH THE THEN ACTIVE FDA'S 1987 GUIDANCE ON LAL TESTING FOR ENDOTOXINS (GUIDELINE ON VALIDATION OF THE LIMULUS AMEBOCYTE LYSATE TEST AS AN END-PRODUCT ENDOTOXIN TEST FOR HUMAN AND ANIMAL PARENTERAL DRUGS, BIOLOGICAL PRODUCTS, AND MEDICAL DEVICES). BACTERIN ADOPTED THIS RETESTING POLICY ON (B)(6) 2011. IN THE EVENT OF AN INITIAL ENDOTOXIN LEVEL FAILURE, TWO SUCCESSIVE ASSESSMENTS ON THE SAME SAMPLE COULD BE PERFORMED. IF THE TWO SUCCESSIVE TESTS PASSED, THE INITIAL FAILED ASSESSMENT WOULD BE CONSIDERED INVALID AND THE SAMPLE DEEMED ACCEPTABLE. AFTER THE (B)(6) 2011, WITHDRAWAL OF THE 1987 GUIDANCE DOCUMENT, BACTERIN'S RETESTING PROCEDURE WAS NOT VALIDATED PRIOR TO ACCEPTANCE AND IS ASSOCIATED WITH AN OBSERVATION IN FDA WARNING LETTER SEA13-10.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
110110 OSTEOSELECT DBM PUTTY DEMINERALIZED BONE MATRIX MQV BACTERIN INTERNATIONAL, INC. SEE ATTACHED SEE ATTACHED

Patients

Seq Age Sex Outcome Treatment
1 NA